Phase i study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced cancer

Journal of Clinical Oncology

Volumn 34, Issue 15, 2016, Pages 1764-1771

  Hong, David ^a   Infante, Jeffrey ^b,c   Janku, Filip ^a   Jones, Suzanne ^b   Nguyen, Ly M ^a   Burris, Howard ^b,c   Naing, Aung ^a   Bauer, Todd M ^b,c   Piha Paul, Sarina ^a   Johnson, Faye M ^a   Kurzrock, Razelle ^a   Golden, Lisa ^d   Hynes, Scott ^d   Lin, Ji ^d   Lin, Aimee Bence ^d   Bendell, Johanna ^b,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SARAH CANNON RESEARCH INSTITUTE   (United States)

^c Tennessee Oncology   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PREXASERTIB; CHECKPOINT KINASE 1; PROTEIN KINASE INHIBITOR; PYRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANIMAL MODEL; ANUS CARCINOMA; ANUS SQUAMOUS CELL CARCINOMA; ARTICLE; CIRCULATING TUMOR CELL; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; DRUG HAIR LEVEL; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ELIMINATION HALF-LIFE; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INCIDENCE; LEUKOPENIA; LUNG INFECTION; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OPEN STUDY; ORAL MUCOSITIS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SKIN ULCER; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOLUME OF DISTRIBUTION AT STEADY-STATE; VOMITING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FEMALE; MALE; MIDDLE AGED; NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHECKPOINT KINASE 1; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PYRAZINES; PYRAZOLES;

EID: 84969584672     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.5788     Document Type: Article

References (17)

1. Dai Y, Grant S: New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 16:376-383, 2010
2. McNeely S, Beckmann R, Bence Lin AK: CHEK again: Revisiting the development of CHK1 inhibitors for cancer therapy. Pharmacol Ther 142: 1-10, 2014
3. King C, Diaz HB, McNeely S, et al: LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms. Mol Cancer Ther 14:2004-2013, 2015
4. Wu W, Bi C, Bence Lin AK, et al: Antitumor activity of Chk1 inhibitor LY2606368 as a single agent in SW1990 human pancreas orthotopic tumor model. Proc Am Assoc Cancer Res 72, 2012 (abstr 1776)
5. Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009
6. National Cancer Institute: Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 4.02. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-Quick Reference-8.5x11.pdf
7. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006
8. Sausville E, Lorusso P, Carducci M, et al: Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol 73:539-549, 2014
9. Seto T, Esaki T, Hirai F, et al: Phase I, doseescalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol 72:619-627, 2013
10. Daud AI, Ashworth MT, Strosberg J, et al: Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol 33:1060-1066, 2015
11. Infante JR, Hollebecque A, Postel-Vinay S, et al: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors. Proc Am Assoc Cancer Res 75:15s, 2015 (suppl; abstr CT139)
12. Ho AL, Bendell JC, Cleary JM, et al: Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors. J Clin Oncol 29, 2011 (suppl; abstr 3033)
13. Calvo E, Chen VJ, Marshall M, et al: Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Invest New Drugs 32:955-968, 2014
14. OmicSoft Corporation: Omicsoft Oncoland TCGA dataset. http://www.omicsoft.com
15. Gadhikar MA, Sciuto MR, Alves MV, et al: Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther 12:1860-1873, 2013
16. Lecona E, Fernández-Capetillo O: Replication stress and cancer: It takes two to tango. Exp Cell Res 329:26-34, 2014
17. Meuth M: Chk1 suppressed cell death. Cell Div 5:21, 2010